Flomics utilizes next-generation sequencing of cell-free RNA to detect cancer by analyzing expression patterns in blood samples, enabling early diagnosis before symptoms arise. This non-invasive liquid biopsy approach provides accurate diagnostics for at-risk individuals, improving screening outcomes and patient care.
Funding
$3.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current cancer screening methods often detect the disease at later stages, reducing treatment options and increasing mortality rates. Traditional diagnostic approaches can be invasive, costly, and may not be suitable for frequent monitoring of at-risk individuals. There is a need for more accessible and less invasive methods for early cancer detection.
Solution
Flomics offers a non-invasive liquid biopsy solution for early cancer detection, utilizing next-generation sequencing (NGS) of cell-free RNA (cfRNA) from blood samples. By analyzing the expression patterns of RNA molecules in circulation, the test can identify disease signatures before the onset of symptoms. The technology combines optimized protocols for RNA extraction and sequencing with machine learning techniques to produce reliable and reproducible results. This approach provides a comprehensive snapshot of organ health, enabling early diagnosis and improved screening outcomes for at-risk individuals.
Target Audience
The primary target audience includes individuals at high risk of developing cancer, healthcare providers seeking advanced diagnostic tools, and clinical partners involved in early-stage screening programs.
Features
- Next-generation sequencing (NGS) of cell-free RNA (cfRNA) for comprehensive analysis of RNA expression patterns.
- Proprietary RNA extraction and sequencing protocols optimized for liquid biopsy applications.
- Machine learning algorithms for identifying cancer-specific signatures and biomarkers.
- Non-invasive blood test suitable for frequent monitoring.
- Early detection capabilities, identifying cancer before symptoms appear.
- Cloud-based platform for data analysis and reporting.